Quest Diagnostics Inc (DGX) Stock AnalysisDGXStock AnalysisQuest Diagnostics Inc

Quest Diagnostics Incorporated is a provider of diagnostic information services. It provides diagnostic insights from the results of its laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and its connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. Its other customers include health plans, employers, emerging retail healthcare providers, government agencies, and others. Its services are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Quest Diagnostics Inc is a good buy right now due to its strong revenue growth and positive market sentiment. The current price is $242.76, and the company has raised its full-year revenue forecast to approximately $12 billion, reflecting a robust demand for its services. Additionally, the RSI is at 57.91, indicating a healthy momentum without being overbought. However, the main risk is the recent 5-day change of -0.67%, suggesting some short-term volatility.

20 analysts cover DGX: 5 rate it Buy, 14 Hold and 1 Sell. The average price target is 203.33.